20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
Open accessAbstract
Antipsychotics are effective in preventing relapses of schizophrenia, but it is generally believed that their long‐term use is harmful for patients’ physical well‐being. However, there are no long‐term studies which have verified this view. This nationwide, register‐based cohort study aimed to assess the risk of hospitalization due to physical health problems, as a marker for severe physical morbidity, and the risk of all‐cause mortality, as well as of cardiovascular and suicidal death, associated with antipsychotic use in all patients treated for schizophrenia in inpatient care between 1972 and 2014 in Finland (N=62,250), with up to 20 years of follow‐up (median: 14.1 years). The use of antipsychotic drugs (i.e., use of any antipsychotic compared with non‐use) and the use of specific antipsychotics were investigated, and outcomes were somatic and cardiovascular hospitalization, and all‐cause, cardiovascular and suicide death. Hospitalization‐based outcomes were analyzed by a within‐individual design to eliminate selection bias, comparing use and non‐use periods in the same individual by stratified Cox model. Mortality outcomes were assessed by traditional between‐individual Cox multivariate models. The adjusted hazard ratios (aHRs) for any somatic hospitalization and cardiovascular hospitalization were 1.00 (95% CI: 0.98‐1.03) and 1.00 (95% CI: 0.92‐1.07) during use of any antipsychotic compared to non‐exposure periods within the same individual. The aHRs were 0.48 (95% CI: 0.46‐0.51) for all‐cause mortality, 0.62 (95% CI: 0.57‐0.67) for cardiovascular mortality, and 0.52 (95% CI: 0.43‐0.62) for suicide mortality during use vs. non‐use of any antipsychotic. The most beneficial mortality outcome was associated with use of clozapine in terms of all‐cause (aHR=0.39, 95% CI: 0.36‐0.43), cardiovascular (aHR=0.55, 95% CI: 0.47‐0.64) and suicide mortality (aHR=0.21, 95% CI: 0.15‐0.29). The cumulative mortality rates during maximum follow‐up of 20 years were 46.2% for no antipsychotic use, 25.7% for any antipsychotic use, and 15.6% for clozapine use. These data suggest that long‐term antipsychotic use does not increase severe physical morbidity leading to hospitalization, and is associated with substantially decreased mortality, especially among patients treated with clozapine.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729 · see citing works
Self-citationTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · see citing works
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271 · see citing works
Self-citationMetabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · see citing works
Vancampfort, D., Firth, J., Schuch, F. B., Rosenbaum, S., Mugisha, J., Hallgren, M., Probst, M., Ward, P. B., Gaughran, F., De Hert, M., et al. (2017) · World Psychiatry · doi:10.1002/wps.20458 · Cited by 957 · see citing works
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · see citing works
Stubbs, B., Vancampfort, D., Hallgren, M., Firth, J., Veronese, N., Solmi, M., Brand, S., Cordes, J., Malchow, B., Gerber, M., et al. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.07.004 · Cited by 697 · see citing works
Self-citationVancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659 · see citing works
Self-citationComorbidities and mortality in persons with schizophrenia: a Swedish national cohort study
Crump, C., Winkleby, M. A., Sundquist, K., & Sundquist, J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12050599 · Cited by 619 · see citing works
Vermeulen, J. M., van Rooijen, G., van de Kerkhof, M. P. J., Sutterland, A. L., Correll, C. U., & de Haan, L. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby052 · Cited by 246 · see citing works
Self-citationCarbon, M., Kane, J. M., Leucht, S., & Correll, C. U. (2018) · World Psychiatry · doi:10.1002/wps.20579 · Cited by 214 · see citing works
Taipale, H., Mehtälä, J., Tanskanen, A., & Tiihonen, J. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx176 · Cited by 153 · see citing works
Self-citationKhan, A., Faucett, J., Morrison, S., & Brown, W. A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.149 · Cited by 109 · see citing works
Flagged first, then by citations
Research works printed but not linked: 27
- Rummel-Kluge C, Komossa K, Schwarz S et al. Second-generation antipsy- chotic drugs and extrapyramidal side effects: a systematic review and meta- analysis of head-to-head comparisons. Schizophr Bull 2012;38:167-77.
- Correll CU, Detraux J, De Lepeleire J et al. Effects of antipsychotics, anti- depressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015;14:119-36.
- Firth J, Siddiqi N, Koyanagi A et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lan- cet Psychiatry 2019;6:675-712.
- Papola D, Ostuzzi G, Gastaldon C et al. Antipsychotic use and risk of life- threatening medical events: umbrella review of observational studies. Acta Psychiatr Scand 2019;140:227-43.
- Henderson DC, Vincenzi B, Andrea NV et al. Pathophysiological mecha- nisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2015;2:452-64.
- Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35.
- Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 2018;17:149-60.
- Hjorthøj C, Stürup AE, McGrath JJ et al. Years of potential life lost and life ex- pectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017;4:295-301.
- Tanskanen A, Tiihonen J, Taipale H. Mortality in schizophrenia: 30-year na- tionwide follow-up study. Acta Psychiatr Scand 2018;138:492-9.
- Schneider-Thoma J, Efthimiou O, Huhn M et al. Second-generation antipsy- chotic drugs and short-term mortality: a systematic review and meta-anal- ysis of placebo-controlled randomised controlled trials. Lancet Psychiatry 2018;5:653-63.
- Tiihonen J, Mittendorfer-Rutz E, Torniainen M et al. Mortality and cumu- lative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psy- chiatry 2016;173:600-6.
- Taipale H, Mittendorfer-Rutz E, Alexanderson K et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schiz- ophr Res 2018;197:274-80.
- Tiihonen J, Tanskanen A, Taipale H. 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 2018;175:765-73.
- Tanskanen A, Taipale H, Koponen M, et al. From prescription drug pur- chases to drug use periods -a second generation method (PRE2DUP). BMC Med Inform Decis Mak 2015;15:21.
- Lichtenstein P, Halldner L, Zetterqvist J et al. Medication for attention defi- cit-hyperactivity disorder and criminality. N Engl J Med 2012;367:2006-14.
- Ventriglio A, Gentile A, Bonfitto I et al. Suicide in the early stage of schizo- phrenia. Front Psychiatry 2016;7:116.
- Vermeulen J, Van Rooijen G, Doedens P et al. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med 2017;47:2217-28.
- Lahti M, Tiihonen J, Wildgust H et al. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. Psychol Med 2012;42: 2275-85.
- Correll CU, Druss BG, Lombardo I et al. Findings of a U.S. national cardio- metabolic screening program among 10,084 psychiatric outpatients. Psy- chiatr Serv 2010;61:892-8.
- Mitchell AJ, Delaffon V, Vancampfort D et al. Guideline concordant monitor- ing of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012;42:125-47.
- Morrato EH, Druss B, Hartung DM et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010;67:17- 24.
- Sisti LG, Dajko M, Campanella P et al. The effect of multifactorial lifestyle interventions on cardiovascular risk factors: a systematic review and meta- analysis of trials conducted in the general population and high risk groups. Prev Med 2018;109:82-97.
- Yuen JWY, Kim DD, Procyshyn RM et al. Clozapine-induced cardiovascular side effects and autonomic dysfunction: a systematic review. Front Neuro- sci 2018;12:203.
- Abela AR, Li Z, Lê AD et al. Clozapine reduces nicotine self-administration, blunts reinstatement of nicotine-seeking but increases responding for food. Addict Biol 2019;24:565-76.
- Howes OD, McCutcheon R, Agid O et al. Treatment-resistant schizophre- nia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychia- try 2017;174:216-29.
- Bitter I, Czobor P, Borsi A et al. Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study. Eur Psychiatry 2017;45:97-103.
- Tanskanen A, Taipale H, Koponen M et al. Drug exposure in register-based re- search -an expert-opinion based evaluation of methods. PLoS One 2017;12: e0184070. DOI:10.1002/wps.20699 20515545, 2020, 1, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/wps.20699, Wiley Online Library on [29/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License · DOI
Cited by
Sorted by citations
Cardiovascular disease in patients with severe mental illness
Nielsen, R. E., Banner, J., & Jensen, S. E. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00463-7 · Cited by 389 · see citing works
Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Achtyes, E. D., Gibbons, R. D., & Robinson, D. G. (2020) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2020.2076 · Cited by 210 · see citing works
Self-citationCroatto, G., Vancampfort, D., Miola, A., Olivola, M., Fiedorowicz, J. G., Firth, J., Alexinschi, O., Gaina, M. A., Makkai, V., Soares, F. C., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01770-w · Cited by 66 · see citing works
Self-citation
- Authors
- Taipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tiihonen, J.
- Affiliations
- University of Eastern Finland (FI)
- EPID Research Oy Espoo Finland
- Northwell Health (US)
- Venue
- World Psychiatry
- Publisher
- Wiley
- Published
- 2020-01-10
- Volume
- 19
- Issue
- 1
- Pages
- 61-68
- ISSN
- 1723-8617 (ISSN-L)
- 2051-5545
- PMC
- PMC6953552
- OpenAlex
- W2998819434
- Cited by
- 415
- References
- 13
- Citations by year
- 2026: 53 · 2025: 63 · 2024: 60 · 2023: 66 · 2022: 79 · 2021: 59 · 2020: 34
- FWCI
- 43.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- World Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- WOS
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Historical Psychiatry and Medical Practices
- Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
- Keywords
- antipsychotic drugs, schizophrenia, physical morbidity, all-cause mortality, cardiovascular mortality, suicide mortality, cardiovascular hospitalization, clozapine, long-term antipsychotic use, Finland, adverse drug reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
